Stay updated on FT218 Efficacy in Narcolepsy: Clinical Trial

Sign up to get notified when there's something new on the FT218 Efficacy in Narcolepsy: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FT218 Efficacy in Narcolepsy: Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:10:18.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or modification in the dosage or effectiveness of the medication FT218 for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.
    Difference
    0.1%
    Check dated 2024-06-06T14:19:56.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for subjects with narcolepsy who are on stable doses of sodium oxybate and are willing to switch to FT218. Previously, no information was provided about the participation criteria.
    Difference
    22%
    Check dated 2024-05-22T20:23:52.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:39:24.000Z thumbnail image

Stay in the know with updates to FT218 Efficacy in Narcolepsy: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FT218 Efficacy in Narcolepsy: Clinical Trial page.